What is Adimab?
Adimab operates at the intersection of biotechnology and enterprise-level drug development. The company provides a sophisticated yeast-based platform that streamlines the discovery, engineering, and optimization of therapeutic antibodies. By offering flexible collaboration models, Adimab enables biopharma partners to bypass traditional bottlenecks in the drug development lifecycle, significantly improving the speed and efficacy of bringing new treatments to market. Its market position is defined by a proven track record of advancing complex therapeutic programs, making it an indispensable partner for organizations seeking to enhance their clinical pipelines through precision engineering and high-throughput screening.
How much funding has Adimab raised?
Adimab has raised a total of $32M across 4 funding rounds:
Series A
$6M
Series D
$8.2M
Series E
$4M
Series F
$13.8M
Series A (2007): $6M with participation from SV Health Investors and Polaris Partners
Series D (2010): $8.2M led by Google Ventures, Polaris Partners, Borealis Ventures, SV Life Sciences, and OrbiMed
Series E (2010): $4M, investors not publicly disclosed
Series F (2012): $13.8M featuring Google Ventures, Polaris Partners, and SV Life Sciences
Key Investors in Adimab
SV Health Investors
A specialist investment firm backing innovative health care and life science companies, partnering with founders to provide capital and sector expertise.
Polaris Partners
A venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors with deep operational support.
Google Ventures
A global venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences and frontier technology innovations.
What's next for Adimab?
Looking ahead, Adimab is positioned to leverage its recent capital injection to further refine its antibody engineering suite and expand its footprint in the multispecific therapeutic space. The company's strategic roadmap focuses on deepening its integration within the global biopharma ecosystem, potentially exploring new frontiers in therapeutic modalities. With a stable foundation of institutional support and a proven business model, Adimab is well-equipped to navigate the complexities of the healthcare innovation cycle, ensuring that its partners remain at the forefront of patient-centric drug development. The focus remains on scaling operational capacity while maintaining the high-quality standards that have defined its reputation in the life sciences sector.
See full Adimab company page
